Therapeutic Efficacy Clinical Trial
Official title:
Comparative Study for the Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser (532nm)
Comparative split face study in which 30 patients with freckles are recruited.One side of the face will be treated with Q Switched (QS)KTP 532nm, and the other side will be treated with intradermal tranexamic acid (TXA).
One side of the face will receive QS KTPlaser at a wavelength of 532 nm, spot size 2-3 mm ,
power 1-1.5J/cm2 and the clinical end point is just frosting.Sessions will be every month for
2 months.
The other side of the face will be assigned to TXA intradermal microinjection in the same
session using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml
syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied
intradermally on freckles area at.
The sessions of TXA will be every 2 weeks for 2 months.
Postoperatively, topical antibiotic ointment and steriod will be applied. Sunscreen then
applied until the next treatment in order to minimize reactive hyperpigmentations.
Follow up after treatment monthly for 2 month.
;